Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an oral combination drug containing three active ingredients: - Paracetamol (also known as acetaminophen): a non-opioid analgesic and antipyretic that reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system. - Phenylephrine: a sympathomimetic decongestant that acts as an alpha-1 adrenergic receptor agonist to constrict blood vessels in the nasal mucosa, reducing swelling and congestion. - Guaifenesin: an expectorant that increases the volume and reduces the viscosity of respiratory tract secretions, making coughs more productive. The combination is used for temporary relief of symptoms associated with colds or flu such as headache, fever, minor aches and pains, nasal congestion due to allergies or upper respiratory infections (including sinusitis), chest congestion from mucus buildup, and dry cough. It does not treat underlying infections[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + phenylephrine + guaifenesin.